跳至主要内容
临床试验/NCT05612373
NCT05612373已完成不适用

Message Offering Free Round Trip Ride-Share Ride to Pharmacy

University of Pennsylvania1 个研究点 分布在 1 个国家目标入组 300,000 人开始时间: 2022年11月3日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
300,000
试验地点
1
主要终点
COVID bivalent booster receipt

研究概览

简要总结

This experiment is part of a megastudy with a total of ten experimental conditions and a holdout control condition to which patients will be randomly assigned. The focal comparison in this experiment is between a message encouraging vaccination that provides patients with a free round trip ride-share ride to and from any pharmacy near them and a control message telling patients that an updated COVID booster vaccine is waiting for them.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Health Services Research
盲法
Double (Care Provider, Outcomes Assessor)

盲法说明

As treated participants will receive text messages, there is no scope for blinding. Care providers will not be made aware of subjects' participation in the study, or assigned treatment arms. The study team will only receive data on subjects' assigned arms and outcomes at the end of the study.

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
是

入选标准

  • •Exclusion Criteria:
  • •The patient unsubscribed from texts before the send date and time of the patient's SMS/MMS message
  • •The patient received a bivalent COVID booster before the send date and time of the patient's SMS/MMS message.

排除标准

  • •The patient unsubscribed from texts before the send date and time of the patient's SMS/MMS message
  • •The patient received a bivalent COVID booster before the send date and time of the patient's SMS/MMS message.

研究组 & 干预措施

Control condition with "waiting for you" message

Experimental

This control condition will use the text message that the investigators found to be the best performing in their last mega-study of vaccine text messages to recommend a COVID vaccination.

干预措施: COVID Booster text messages (Behavioral)

Message offering free round trip ride to the pharmacy

Experimental

This condition will use a text message offering a free round trip ride to the pharmacy to get a COVID vaccination.

干预措施: COVID Booster text messages (Behavioral)

结局指标

主要结局

COVID bivalent booster receipt

时间窗: During the 30 days after receiving the SMS/MMS intervention

Whether patients receive a bivalent COVID booster at the pharmacy in question

次要结局

  • COVID bivalent booster receipt(90 days after receiving the SMS/MMS intervention)
  • COVID bivalent booster receipt(60 days after receiving the SMS/MMS intervention)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

已完成
不适用
Message From Local Pharmacy TeamCOVID-19
NCT05613764University of Pennsylvania520,000
已完成
不适用
Planning Message Recommending Same Time/Location as Last VaccineCOVID-19
NCT05612386University of Pennsylvania520,000
已完成
不适用
Message Communicating Latest Data on COVID-19 Transmission in Patient's AreaCOVID-19
NCT05621226University of Pennsylvania520,000
进行中(未招募)
不适用
Estudio piloto, abierto, comparativo y multicéntrico de 2 brazos para evaluar la eficacia y seguridad de un período de extensión de 12 semanas con peginterferon a-2b y ribavirina versus un brazo de duración estándar de tratamiento, en pacientes co-infectados por el VIH y Hepatitis C crónica con respuesta virológica precoz lenta”Hepatitis C Crónica
EUCTR2005-004699-19-ESDr. V. Soriano
进行中(未招募)
1 期
Ensayo clínico mundial, abierto, para analizar la seguridad y tolerabilidad a largo plazo de rizatriptán en el tratamiento de la migraña, con o sin aura, de niños migrañosos. // A Worldwide, Open Label, Clinical Trial to Examine the Long Term Safety and Tolerability of Rizatriptan in Pediatric Migraineurs for the Treatment of Migraine With or Without Aura.Tratamiento a largo plazo de la migraña aguda, con o sin aura, en niños y adolescentes, con edades de 12 a 17 años. // Long term treatment of acute migraine, with or without aura, in children and adolescents, ages 12 to 17 years.MedDRA version: 12.0 Level: LLT Classification code 10066635 Term: Acute migraine
EUCTR2009-016375-30-ESMerck & Co., Inc.606